Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
navitoclax (ABT 263)
i
Other names:
RG 7433, RG7433, ABT 263, ABT-263, RG 7423, RG7423
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(19)
News
Trials
Company:
AbbVie
Drug class:
Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
Related drugs:
‹
venetoclax (416)
paclitaxel (178)
albumin-bound paclitaxel (67)
APG-1252 (8)
APG-2575 (7)
micellar paclitaxel (3)
APG1244 (2)
AR160 (2)
BGB-11417 (2)
ABBV-167 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
ABBV-453 (0)
AZD0466 (0)
AZD4320 (0)
BGB-21447 (0)
Bcl-2 Family Inhibitors (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
FCN-338 (0)
FCN-683 (0)
oblimersen (0)
KLTi (0)
L105 (0)
LP-108 (0)
LP-118 (0)
liposomal paclitaxel (0)
MRX34 (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
S65487 (0)
SPC2996 (0)
TQB3909 (0)
TW-37 (0)
ZN-d5 (0)
BP1002 (0)
FID-007 (0)
GX 15-070 (0)
ANG1005 (0)
PNT2258 (0)
ONT-701 (0)
A-1331852 (6)
ABBV-637 (0)
ABBV-155 (0)
venetoclax (416)
paclitaxel (178)
albumin-bound paclitaxel (67)
APG-1252 (8)
APG-2575 (7)
micellar paclitaxel (3)
APG1244 (2)
AR160 (2)
BGB-11417 (2)
ABBV-167 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
ABBV-453 (0)
AZD0466 (0)
AZD4320 (0)
BGB-21447 (0)
Bcl-2 Family Inhibitors (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
FCN-338 (0)
FCN-683 (0)
oblimersen (0)
KLTi (0)
L105 (0)
LP-108 (0)
LP-118 (0)
liposomal paclitaxel (0)
MRX34 (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
S65487 (0)
SPC2996 (0)
TQB3909 (0)
TW-37 (0)
ZN-d5 (0)
BP1002 (0)
FID-007 (0)
GX 15-070 (0)
ANG1005 (0)
PNT2258 (0)
ONT-701 (0)
A-1331852 (6)
ABBV-637 (0)
ABBV-155 (0)
›
Associations
(19)
News
Trials
Search handles
@DrBetofMDPhD
@EvanHallMD
@OlofssonBagge
@RahulBanerjeeMD
@StephenVLiu
@doctorpemm
@hemedoc
@weldeiry
Search handles
@DrBetofMDPhD
@EvanHallMD
@OlofssonBagge
@RahulBanerjeeMD
@StephenVLiu
@doctorpemm
@hemedoc
@weldeiry
Filter by
Latest
10ms
Always a pleasure to talk #melanoma with my friend and colleague Zeynep Eroglu from @MoffittNews! She beautifully presented dab/tram/navitoclax for 2L+ melanoma at #ASCO23. @OncoAlert (@DrBetofMDPhD)
10 months ago
navitoclax (ABT 263)
10ms
Allison Betof Warner, MD, PhD, and Zeynep Eroglu, MD, on Metastatic Melanoma: New Data on Dabrafenib, Trametinib, and Navitoclax https://t.co/NRyC5s2BmM #melsm #melanoma #skincancer #oncology #ASCO23 @DrBetofMDPhD @StanfordCancer @MoffittNews (@ASCOPost)
10 months ago
Metastases
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)
11ms
Dr Zeynep Eroglu @MoffittNews presents study of dab/tram +/- Navitoclax in BRAF mutated #melanoma. Interesting biological rationale. Good use of ETCTN mechanism to explore combo. Some unique stats (not designed to directly compare cohorts) given small N. #ASCO23 1/ (@EvanHallMD)
11 months ago
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
navitoclax (ABT 263)
11ms
Unfortunately no added major efficacy adding navitoclax to BRAF/MEKi in advanced melanoma, even though formally meeting the primary endpoint CR 20% compared to historical controls. #ASCO23 #melSM (@OlofssonBagge)
11 months ago
Clinical • Metastases
|
BRAF (B-raf proto-oncogene)
|
navitoclax (ABT 263)
1year
There are open trials for inhibitors of pro-survival proteins (to induce apoptosis) in solid tumors. Mostly targeting BCL-XL: APG-1252: https://t.co/9jAWOAIpcl Navitoclax: https://t.co/GqXE5oNY6q DT-2216: https://t.co/9rLuxPsx0d (@CellDeathLab)
1 year ago
BCL2L1 (BCL2-like 1)
|
navitoclax (ABT 263) • pelcitoclax (APG-1252) • DT2216
1year
New preclinical #eldeirylab results Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis https://t.co/zDEeFyrBHr (@weldeiry)
1 year ago
Preclinical • Tumor cell
|
MCL1 (Myeloid cell leukemia 1)
|
navitoclax (ABT 263) • dordaviprone (ONC201)
2years
#AACR22 Please come on by our Late-Breaking Research Poster #2 9AM-12 today: #Navitoclax https://t.co/uYVafqCT5R… | #BCLxL #JAK2 #apoptosis @doctorpemm @harrisoncn1 @sk_tantravahi @MDAndersonNews @Lisa_Palacios #leusm #MPNSM #endcancer | @AACR (@doctorpemm)
2 years ago
Late-breaking abstract
|
JAK2 (Janus kinase 2) • BCL2L1 (BCL2-like 1)
|
navitoclax (ABT 263)
2years
#AACR22 Delighted to present our Late-Breaking Research Poster #Navitoclax https://t.co/DXz5QlQ7QO | #BCLxL #JAK2 #apoptosis @doctorpemm @harrisoncn1 @sk_tantravahi @MDAndersonNews @Lisa_Palacios #leusm #MPNSM #endcancer | @AACR (@doctorpemm)
2 years ago
Late-breaking abstract
|
JAK2 (Janus kinase 2) • BCL2L1 (BCL2-like 1)
|
navitoclax (ABT 263)
2years
#AACR22 | Our multi-center group’s latest findings #Navitoclax + Ruxolitinib program jn Myelofibrosis | @doctorpemm @sk_tantravahi @harrisoncn1 | #MPNSM #BCLxL #leusm | #LBA Late Breaking Abstract Session https://t.co/DXz5QlQ7QO (@doctorpemm)
2 years ago
Clinical • Late-breaking abstract
|
BCL2L1 (BCL2-like 1)
|
Jakafi (ruxolitinib) • navitoclax (ABT 263)
2years
Congrats @doctorpemm et al! Chapter still being written on BCL-Xᴸ (navitoclax targets both this & BCL2). E.g. in #MMsm, @MCT_AACR paper shows BCL-Xᴸ drives Ven and Ven-Vd #BELLINI resistance as much as MCL1. https://t.co/CqDvMJlTi1 ⬇️ PLTs as navitoclax's DLT manageable here. (@RahulBanerjeeMD)
2 years ago
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
|
navitoclax (ABT 263)
over2years
#WCLC21 Dr. Li Zhang with pelcitoclax (APG-1252, Bcl-2 inhibitor) + osimertinib in #EGFR TKI resistant NSCLC. Main tox platelets, LFTs. Post 3rd gen TKI, confirmed RR 5%. In treatment naive, confirmed RR 36% (8/22). No case over osi alone. Like navitoclax, this needs a biomarker. (@StephenVLiu)
over 2 years ago
Clinical • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
Tagrisso (osimertinib) • navitoclax (ABT 263) • pelcitoclax (APG-1252)
3years
#OnlineFirst: Combination of #navitoclax and #osimertinib in patients with EGFR mutant #NSCLC proves tolerable and shows compelling efficacy with durable responses and complete clearance of #ctDNA. @ryangentzler @ZPiotrowskaMD @geoff_oxnard https://t.co/WxKC8oH2tA (@CCR_AACR)
3 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • navitoclax (ABT 263)
over3years
#ASH20 #leusm Rubnitz: Ven + Navitoclax (adds BCLxl inhib to BCL2 inhib) in peds R/R ALL, N=18, 56% CR (70% MRD neg). (@hemedoc)
over 3 years ago
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
|
navitoclax (ABT 263)
over3years
#ASH20 Awesome learning perspective for me to present our work on #Navitoclax #BCLXL inhibition in patients with Myelofibrosis on the same day as the #HamWasserman Lecture from Dr Andrew Roberts #BCL2 #BCLXL #MCL1 #BAX @ASH_hematology #ASHFromHome #ASHTogether #MPNSM #leusm (@doctorpemm)
over 3 years ago
Clinical
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
|
navitoclax (ABT 263)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login